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ABSTRACT
Severe asthma is a subtype of asthma that is
difficult to treat and control. By conservative
estimates, severe asthma affects approximately
5–10% of patients with asthma worldwide.
Severe asthma impairs patients’ health-related
quality of life, and patients are at risk of life-
threatening asthma attacks. Severe asthma also
accounts for the majority of health care
expenditures associated with asthma. Guideli-
nes recommend that patients with severe
asthma be referred to a specialist respiratory
team for correct diagnosis and expert manage-
ment. This is particularly important to ensure
that they have access to newly available biologic
treatments. However, many patients with severe
asthma can suffer multiple asthma attacks and
wait several years before they are referred for
specialist care. As global patient advocates, we
believe it is essential to raise awareness and
understanding for patients, caregivers, health
care professionals, and the public about the
substantial impact of severe asthma and to cre-
ate opportunities for improving patient care.
Patients should be empowered to live a life free
of symptoms and the adverse effects of tradi-
tional medications (e.g., oral corticosteroids),
reducing hospital visits and emergency care, the
loss of school and work days, and the con-
straints placed on their daily lives. Here we
provide a Patient Charter for severe asthma,
consisting of six core principles, to mobilize
national governments, health care providers,
payer policymakers, lung health industry part-
ners, and patients/caregivers to address the
unmet need and burden in severe asthma and
ultimately work together to deliver meaningful
improvements in care.
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INTRODUCTION
Worldwide, up to 334 million people are esti-
mated to be living with asthma [1]. Patients
with asthma experience respiratory symptoms,
such as wheezing, shortness of breath, chest
tightness, cough, and airway obstruction, that
can vary over time [2]. Overall, asthma is often
regarded as a controllable condition, but
asthma constitutes a significant public health
problem across all countries, regardless of
development level [3]. Asthma varies between
individual patients in its underlying disease
mechanisms, the type and intensity of symp-
toms, and treatment response [2]. Some sub-
types, such as severe asthma, do not fully
respond to established treatments. In 2010,
345,000 asthma-related deaths were reported
worldwide (Fig. 1) [1, 4]. Many of these asthma-
associated deaths potentially could have been
prevented with improved patient management,
more complete implementation of existing
recommendations, and increased access to spe-
cialist care [5–7].
Severe asthma is hard to control and affects
5–10% of patients with asthma [8]. This may be
a conservative estimate. For many patients with
severe asthma, symptoms do not improve with
the usual standard of care [inhaled corticos-
teroids (ICS)], even when medicines are taken
correctly and other potential causes of symp-
toms have been ruled out [8]. Therefore, tradi-
tional treatments are either less effective for
these patients or must be taken in extremely
high dosages, exposing patients to associated
and substantial adverse effects. Patients with
severe asthma also have more frequent life-
threatening asthma attacks, which can have a
devastating impact on people’s lives [9]. The
struggle to breathe can be a day-to-day chal-
lenge that overshadows much of the sufferer’s
daily activities, potentially resulting in hospital
admissions, intensive care, and even death
[9, 10].
In addition to the burden on the individual
with severe asthma, the disease impacts on
health systems and society [11]. The relatively
small severe asthma patient population drives a
significant percentage of health care cost, esti-
mated in some countries to be 50% of all
asthma-related costs [12]. In other health sys-
tems, the care required to treat a patient with
severe asthma can be up to five times more
expensive than the care required for mild
asthma ($1579 vs. $298 US dollars, respectively)
[11].
Guidelines written by the American Thoracic
Society (ATS) and the European Respiratory
Society (ERS) in 2014 are recognized as the best
clinical guidance for severe asthma diagnosis
and treatment [8]. However, understanding of
the biology and needs of patients with severe
asthma is rapidly evolving, and new treatments
(e.g., biologics) are being introduced [13].
Approaches to care must reflect these changes
and the increasing treatment options available.
In response to these changes, we, as represen-
tatives of the academic treating community,
patient support groups, and professional orga-
nizations, have developed a Patient Charter for
the care of patients with severe asthma with six
principles for consideration (see Box 1 in
Appendix). These principles set out to define
what patients should expect for the manage-
ment of their severe asthma and what should
constitute a basic standard of care, in line with
the latest science and best practice under-
standing from existing severe asthma care
services.
PRINCIPLE 1: I DESERVE A TIMELY,
STRAIGHTFORWARD REFERRAL
WHEN MY SEVERE ASTHMA
CANNOT BE MANAGED
IN PRIMARY CARE
Internationally recognized guidelines for the
management of asthma state that severe asthma
is a complex condition that requires input from
experts to confirm the diagnosis and for
appropriate management [6, 8]. However, peo-
ple with severe asthma often experience several
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asthma attacks (also known as exacerbations)
and admission to emergency departments
before they are referred for specialist care [6, 7].
Some patients spend up to 7 years experiment-
ing with different treatments and suffering from
associated debilitating treatment adverse effects
Fig. 1 Age-standardized asthma mortality rates for asthma
overall for all ages, 2001–2010 [1]. Average number of
deaths and average population for each 5-year age group
over the period 2001–2010, using all available data for
each country (the number of available years over this
period ranged from 1 to 10). Reproduced with kind
permission from the Global Asthma Network from:
Global Asthma Network. The Global Asthma Report
2014. http://www.globalasthmareport.org/resources/
Global_Asthma_Report_2014.pdf
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before being referred to a respiratory specialist
[6, 9, 14]. Four patient journey phases were
identified from semistructured in-depth inter-
views with a small sample of patients from The
Netherlands diagnosed with severe asthma:
‘‘looking for a solution,’’ ‘‘recognition and
hope,’’ ‘‘given up,’’ and ‘‘accepting the disease’’
(Fig. 2) [15]. During this lengthy journey, severe
asthma was reported to dominate patients’
lives, making it difficult for them to live the
lives they imagined [15]. Shortening the patient
journey is key to improving the health-related
quality of life for patients with severe asthma.
However, it appears that many health care
professionals do not recognize severe asthma as
a distinct form of asthma. They perhaps pre-
sume that people with regularly uncontrolled
symptoms have poorly controlled mild/moder-
ate asthma caused by poor treatment
adherence.
Patients who present to their general practi-
tioner with difficult-to-manage asthma should
be adequately assessed using a structured
methodology, such as the ‘‘SIMPLES’’ approach,
before severe asthma is considered and the
patient is referred to a severe asthma specialist
clinic [16]. The ‘‘SIMPLES’’ approach, aligned
with cooperation between primary and special-
ist care, can avoid inappropriate escalation of
treatment, streamline clinical assessment and
management, and optimize patient referrals
[16]. Patients and health care professionals
should also have access to a simple, under-
standable set of criteria for identifying severe
asthma based on best practice guidance, such as
the ATS/ERS and Global Initiative for Asthma
(GINA) guidelines [2, 8]. In general, patients
experiencing any of the following should be
referred to an expert respiratory physician: oral
corticosteroid (OCS) use for[3 months, more
than two rounds of OCS treatment in the past
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Fig. 2 Patient perspective on severe asthma: four phases of
the patient journey [15]. Results based on semistructured
in-depth interviews with patients (and their relatives) in
their own homes that lasted * 2 h. All patients were
diagnosed with severe asthma by a pulmonologist (six
patients were diagnosed with severe allergic disease). No
patients had a diagnosed comorbidity with symptoms
similar to asthma. aAdmission to Heideheuvel/Davos.
Reproduced with kind permission from Beautiful Lives,
Hilversum, The Netherlands
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12 months, hospitalization for asthma in the
past 12 months, or impaired lung function
despite optimized standard therapy.
Education within the health care and patient
communities on these referral criteria would
facilitate rapid referral, and systems already in
place in many health authorities could be used
to automate this process. Studies have reported
that patients under the care of an asthma spe-
cialist have a reduced risk of being hospitalized
for an asthma attack compared with those being
managed by a nonspecialist [6].
PRINCIPLE 2: I DESERVE A TIMELY,
FORMAL DIAGNOSIS OF MY SEVERE
ASTHMA BY AN EXPERT TEAM
An accurate diagnosis is the foundation of
effective asthma care [2, 6]. An initial diagnosis
of asthma usually occurs in primary care, based
on objective testing over a period of time.
However, a formal diagnosis of severe asthma
requires a more complex assessment following
referral to a respiratory specialist [6]. Part of the
reason why a diagnosis of severe asthma is
complex is the lack of a clear and consistently
used definition of severe asthma. Definitions of
severe asthma have historically been based on
the degree of symptoms, but newer guidance
considers the treatment required to attain con-
trol. According to international guidelines,
asthma is considered severe if, despite the
elimination of modifiable factors (e.g., poor
inhaler technique/adherence, persistent envi-
ronmental exposure to disease triggers), it
requires high-dosage ICS plus a second con-
troller with or without oral OCS to prevent it
from becoming uncontrolled or if it remains
uncontrolled despite this treatment [2].
It is recommended that a diagnosis of severe
asthma should be completed by a specialist
multidisciplinary team (MDT) with access to the
appropriate resources [6, 7, 17]. However, prior
to referral, patients presenting with uncon-
trolled asthma in primary care initially should
be assessed to ensure that their symptoms do
not remain uncontrolled because of factors
other than severe disease [2]. It should first be
determined if patients are taking their
prescribed medication properly, with good
inhaler technique. The presence of uncon-
trolled comorbid conditions that may reduce
the effectiveness of asthma medications (e.g.,
chronic sinusitis, obesity, gastroesophageal
reflux disease) should also be investigated [2].
Measures to improve the accuracy of diagnosis
for patients with mild and moderate asthma
and persistent symptoms caused by poor medi-
cation adherence or triggers other than asthma
would also help to ensure appropriate use of
specialist care [6].
In other conditions, such as rheumatoid
arthritis, cardiovascular disease, and cancer,
there are clear referral pathways and set waiting
time targets to ensure rapid diagnosis [18, 19].
Establishing similar targets and clear referral
pathways for patients with asthma would help
patients receive an accurate, early diagnosis and
appropriate treatment.
PRINCIPLE 3: I DESERVE SUPPORT
TO UNDERSTAND MY TYPE
OF SEVERE ASTHMA
Although severe asthma is complex [20], scien-
tific understanding of the disease is progressing
rapidly. The existence of disease subtypes and
the complexity of the causes of severe asthma,
including genetic, allergic, and environmental
factors, contribute to the requirement for tai-
lored specialist care [9]. Different subtypes of
the disease (known as phenotypes and endo-
types) have been characterized based on
patients’ underlying disease mechanisms, trig-
gers, and responses to treatment (Table 1). Some
biologic markers (substances that can identify
disease processes) have also been identified that
can accurately characterize the underlying cau-
ses of a patient’s disease and how it should be
managed [9, 21]. Thus, the treatment of asthma,
and particularly severe asthma, has moved away
from the established trial-and-error, step-up
method of treatment and toward a more per-
sonalized approach [22]. This follows the trend
toward personalized medicine in other diseases.
Patients with cancer, for example, increasingly
receive treatment with therapies targeted at the
characteristics of their cancer cells, as opposed
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to traditional chemotherapy, which uses drugs
that are toxic to many cells besides cancer cells
[23].
The published European Charter of Patients’
Rights states, ‘‘Each individual has the right to
freely choose from among different treatment
procedures and providers on the basis of ade-
quate information’’ [24]. Patients should receive
relevant information from his or her health care
professional in a simple and clear format to
better understand the treatment options avail-
able and the consequences of different man-
agement approaches. Such provision represents
a definite unmet need for patients with severe
asthma [22].
PRINCIPLE 4: I DESERVE CARE
THAT REDUCES THE IMPACT
OF SEVERE ASTHMA ON MY DAILY
LIFE AND IMPROVES MY OVERALL
QUALITY OF CARE
Severe asthma differs from mild and moderate
asthma, in part because the patient experience
is much worse. Symptoms can affect relation-
ships, careers, parenting, and social lives, and
sometimes patients’ abilities to undertake the
most basic daily tasks [25]. Patients with severe
asthma also have more frequent life-threatening
asthma attacks, resulting in hospital admission
and potentially death [9]. Furthermore, the
Table 1 Summary of recognized asthma subtypes (endotypes and phenotypes) based on disease characteristics, treatment
response, and disease mechanisms
Description Markers
associated with
the disease
Disease
onset
Clinical features
Allergic asthma Blood IgE [36] Early/
childhood
[37]
Genetic tendency to develop allergies is associated with all
asthma types, but prevalence is increased in those with early
onset [37]
Eosinophilic
asthma
Eosinophils (IL-5)
[38]
Late/adult
[39]
Blood/sputum eosinophil count is a predictive biomarker for
increased severity of asthma attacks [40]
Targeting eosinophils may improve asthma control [39]
Aspirin-exacerbated
respiratory
disease
Eosinophils, also
IgE
Late/adult Often severe and exhibits sinusitis and nasal polyposis
Presents as an NSAID allergy
May be genetic [41]
Neutrophilic
asthma
Neutrophils (IL-8) Late/adult
[42]
Neutrophils in the airways are associated with reduced lung
function and thicker airway walls [42]
Typically experienced by patients treated with corticosteroids,
limited management options [42]
Obesity-associated
asthma
Lack of biomarkers
[42]
Late/adult Poor response to corticosteroid therapy [43]
Weight loss may improve symptoms [44]
Exercise-induced
asthma
Cytokines,
leukotrienes
Early Presents intermittently with strenuous exercise
More common in athletes with a genetic tendency to develop
allergies [41]
Ig immunoglobulin, IL interleukin, NSAID nonsteroidal antiinﬂammatory drug
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adverse effects associated with treatments to
manage and prevent such asthma attacks (in-
cluding OCS, on which patients can become
dependent) can also represent a significant
burden for people with severe asthma [26].
The goal of asthma management is to
achieve disease control. The definition of
asthma control is based on symptoms, lung
function, sleep disturbance, limitations of daily
activity, use of rescue medication, and the
overall assessment of patients and physicians
[27]. Assessment of asthma control is used to
inform changes made to a patient’s asthma
management plan and for prompt referral to a
specialist for diagnosis of severe asthma [27].
The benefits of good asthma control include
reduced health care resource utilization, fewer
missed work/school days, and a lesser risk of
asthma attacks [28].
An international study of nonspecialist
physicians treating patients with asthma
reported that only 10% used validated patient
questionnaires to determine if their patients’
asthma was controlled and just 37% of patients
had a written asthma action plan [29]. It has
been reported that many patients with severe
asthma underestimate the severity of their
condition and overestimate how well it is con-
trolled [30]. In addition, as many as 70% of
patients have become accustomed to compro-
mising their daily activities to accommodate
living with severe asthma [10]. GINA guidelines
define goals for asthma treatment and expected
health outcomes. However, a European study
reported that a low percentage of patients with
severe asthma are achieving these goals (Fig. 3)
[10], highlighting the unmet need for improved
treatment and management of patients with
severe asthma.
There is a need to educate patients living
with severe asthma to recognize persistent
symptoms and know to seek expert treatment to
potentially achieve a better health-related
quality of life. Frequent patient education on
correct inhaler technique is also important to
ensure the optimal effect of currently prescribed
medications. There should be shared decision-
making between patients and their clinicians to
ensure that care focuses on limiting the impact
of symptoms and the adverse effects of
treatment on physical, mental, and emotional
health. Each person will be different, so care
should be personalized to address what matters
most to each individual [22].
PRINCIPLE 5: I DESERVE NOT TO BE
RELIANT ON ORAL
CORTICOSTEROIDS
Compared with patients with milder controlled
disease, patients with severe asthma also expe-
rience adverse effects from treatments that are
used to manage asthma attacks (e.g., OCS). If
these treatments are used long term, the
resulting adverse effects may include weight
gain, diabetes, osteoporosis, glaucoma, anxiety,
cardiovascular disease, and impaired immunity
[17]. These can be debilitating, with a signifi-
cant impact on both other conditions that
patients may have and overall health-related
quality of life [9]. Adverse effects also have a
significant impact on the utilization of addi-
tional health care services [31, 32]. Asthma UK
reports that patients ‘‘loathe’’ these treatments
and that the substantial adverse effects are a
significant reason they do not comply with
their prescribed medications, which puts them
at risk of experiencing a future asthma attack
[9, 14]. Now that new, targeted treatment
options based on increased understanding of
the biology of the underlying disease are avail-
able, there is a growing call for severe asthma
care to be less reliant on the long-term use of
OCS to prevent asthma attacks [9].
PRINCIPLE 6: I DESERVE TO ACCESS
CONSISTENT QUALITY CARE,
REGARDLESS OF WHERE I LIVE
OR WHERE I CHOOSE TO ACCESS IT
Severe asthma requires input from a specialist
team to confirm a diagnosis and determine the
best treatment/management approach for indi-
vidual patients [6, 8]. However, management
practices and patients’ experiences of asthma
care exhibit geographic variation, and there is
also inconsistency within countries in how
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patients are managed [6]. A study in seven
European countries reported that management
and control of asthma were below the standard
defined in the GINA guidelines, with most
adults (49.5–73.0%) and many children
(38.4–70.6%) only having a follow-up visit for
their asthma when they experienced an asthma
attack [31, 33]. Furthermore, in our experience,
it can take patients an astounding 10–20 years
to be referred to a respiratory specialist in many
countries.
New care models should be considered for
the delivery of severe asthma services to
improve efficiency and ensure that patients
have access to consistent quality care. Treat-
ment of conditions such as diabetes and stroke
has been transformed using networks and
technology to deliver efficient but effective
specialized care [34]. People with severe asthma
should receive a personalized approach
throughout their treatment journey based on
their own individual needs [22].
DISCUSSION
Severe asthma places a significant burden on
health systems and the lives of patients. Despite
existing treatment guidelines, the management
of patients with severe asthma in practice all too
often fails to sufficiently achieve outlined goals.
There is, therefore, a need to urgently review
the current care provided for patients with
asthma and raise the expectations regarding
their diagnosis and treatment. Improvements in
the quality of care for patients with asthma falls
behind that achieved for other diseases. For
example, a patient experiencing a heart attack
would not be released from the hospital after an
initial attack had been controlled without a
plan for follow up and treatment to prevent
future attacks. Yet this is the experience of
many patients hospitalized for an asthma
attack, even though these patients are very
likely to experience another attack that could be
potentially fatal.
During the past 20 years, the introduction of
biologics for the treatment of rheumatoid
arthritis, along with improved care from a MDT,
has transformed the experience of patients with
this disease. Early diagnosis and effective treat-
ment have resulted in a reduction in the num-
ber of surgeries and hospitalizations required for
the management of rheumatic disease [35].
Steroid therapy is no longer overused. The same
revolution is occurring in the treatment of
patients with severe asthma, with new biologic
treatments becoming available that have
demonstrated effectiveness in reducing future
asthma attacks for patients with defined sub-
types of severe asthma [13]. However, ensuring
that patients with severe asthma who may
Fig. 3 Percentage of patients with severe asthma achieving
international treatment goals [10]. Reproduced with kind
permission from the European Federation of Allergy and
Airways Diseases Patients Association (EFA) from: Euro-
pean Federation of Allergy and Airways Diseases Patients
Association (EFA). A European patient perspective on
severe asthma: Fighting for breath http://www.efanet.org/
images/2012/07/Fighting_For_Breath1.pdf
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potentially benefit from these new treatments
are identified and seen by specialists is funda-
mental to achieving these improvements. Early
diagnosis is particularly important to facilitate
the prescribing of these new biologics or to
enable patients to enroll in clinical studies of
other novel therapies.
To implement these principles, we recom-
mend the following. Asthma patients should
request written asthma treatment action plans
from physicians, with specific goals detailed, as
a mandatory part of the care they receive. They
should also request that both their physicians
and pharmacists provide or make available
training of inhaler technique to them before
they fill new prescriptions. This ‘‘double check’’
can help avoid errors. In addition, patient
organizations should reinforce the need for
written action plans and frequent checks of
inhaler technique. Many patient organizations
have programs to detail what should be in a
written action plan and why is it useful and
often provide instructional recordings demon-
strating correct inhaler techniques. Patient
organization representatives should screen
meeting participants as they demonstrate their
inhaler techniques and review written action
plans to verify they understand them correctly.
The principles we have set out in the Charter
to Improve Patient Care in Severe Asthma
demonstrate the core elements of quality care
that patients with severe asthma should expect
to receive. They are based on the latest under-
standing of the disease and how care should be
structured. These principles should be used to
benchmark current service provision. We urge
policymakers, those responsible for the delivery
of severe asthma care, and advocates for better
care to use the principles and action plan we
have set out here to build consensus on what
severe asthma care should look like in their
health system, place people with asthma at the
center of care, identify the current gaps and
areas for improvement, and implement mea-
sures to improve the quality of care and
outcomes for people with severe asthma with a
view to promoting a life with minimal
symptoms.
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APPENDIX
Box 1: Charter to improve patient care
in severe asthma principles
Principle 1: I deserve a timely, straightforward referral
when my severe asthma cannot be managed in primary
care.
Principle 2: I deserve a timely, formal diagnosis of my
severe asthma by an expert team.
Principle 3: I deserve support to understand my type of
severe asthma.
Principle 4: I deserve care that reduces the impact of severe
asthma on my daily life and improves my overall quality
of care.
Principle 5: I deserve not to be reliant on oral
corticosteroids.
Principle 6: I deserve to access consistent quality care,
regardless of where I live or where I choose to access it.
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